{"id":16277,"date":"2022-06-13T19:59:26","date_gmt":"2022-06-13T17:59:26","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=16277"},"modified":"2024-12-11T15:17:44","modified_gmt":"2024-12-11T14:17:44","slug":"inhibiteur-de-btk-dans-le-pti","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/inhibiteur-de-btk-dans-le-pti\/","title":{"rendered":"Inhibiteur de BTK dans le PTI"},"content":{"rendered":"

R\u00e9f. :HematoStat.net ; 3 (2) : R53<\/p>\n

Kuter DJ, Efraim M, Mayer J, Trn\u011bn\u00fd M, McDonald V, Bird R, et al. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. N Engl J Med. 14 avr 2022;386(15):1421<\/span>\u201131.<\/span><\/i><\/div>\n
<\/div>\n
\n

R\u00e9sum\u00e9<\/h3>\n

Dans cet essai de phase 1-2, 60 patients atteints de purpura thrombop\u00e9nique immunologique (PTI) recevaient le rilzabrutinib, inhibiteur covalent r\u00e9versible de bruton thirosine kinase (iBTK). A la dose cible de 400 mg\/12h, les effets secondaires observ\u00e9s \u00e9taient de grade 1 ou 2 et transitoires. Une r\u00e9ponse (plaquettes \u2265 50 G\/L \u00e0 2 reprises, cons\u00e9cutivement) \u00e9tait obtenue chez 40 % des patients (24 sur 60) apr\u00e8s un d\u00e9lai m\u00e9dian de 11,5 jours.<\/p>\n

Dans nos pratiques<\/h3>\n

Cet iBTK offre une nouvelle approche th\u00e9rapeutique en r\u00e9duisant la production d\u2019anticorps anti-plaquettes et en diminuant l\u2019\u00e9limination des plaquettes par les macrophages. Plus sp\u00e9cifique que les autres iBTK disponibles, aucun \u00e9v\u00e9nement h\u00e9morragique ou passage en fibrillation auriculaire n\u2019\u00e9tait observ\u00e9 dans cet essai.<\/p>\n

Une \u00e9tude de phase 3 contre placebo est en cours afin notamment de confirmer la p\u00e9rennit\u00e9 de ces bons r\u00e9sultats.<\/p>\n<\/div>\n

Le regard du biostatisticien<\/strong><\/h3>\n

Cette publication r\u00e9sume dans le d\u00e9tail les r\u00e9sultats de cette phase I-II de mani\u00e8re descriptive et graphique tr\u00e8s principalement. Celles-ci sont aussi d\u00e9doubl\u00e9es en partant de la population totale de 60 patients et des 45 qui ont d\u00e9but\u00e9 par deux doses journali\u00e8res de rilzabrutinib. Les graphiques se concentrent logiquement sur les r\u00e9sultats plaquettaires, avec un suivi de l\u2019\u00e9volution en ne manquant pas de stipuler les effectifs analys\u00e9s au fil des jours (un point souvent oubli\u00e9 dans ce type de graphique lorsqu\u2019on perd des patients en cours de route). Le swimmer plot<\/em><\/span><\/i><\/i>swimmer plot<\/em> <\/i>offre un tr\u00e8s haut niveau de d\u00e9tails sur les patients et leur taux de plaquettes, doses et \u00e9volution de cette dose, dur\u00e9es de r\u00e9ponse et de traitement, plus les traitements concomitants (glucocortico\u00efdes ou agonistes de r\u00e9cepteurs thrombopo\u00ef\u00e9tine).<\/p>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":16,"featured_media":14595,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[36],"tags":[],"ppma_author":[456],"class_list":["post-16277","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-revue-de-presse","author-alexis-genthon"],"aioseo_notices":[],"authors":[{"term_id":456,"user_id":16,"is_guest":0,"slug":"alexis-genthon","display_name":"Alexis GENTHON","avatar_url":{"url":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2023\/06\/Capture-decran-2021-05-07-a-14.25.02.png","url2x":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2023\/06\/Capture-decran-2021-05-07-a-14.25.02.png"},"first_name":"","last_name":"","user_url":"","description":"H\u00e9matologue.\r\nCorrespondance : H\u00f4pital Saint-Antoine \r\nService h\u00e9matologie clinique\r\n184 rue du Faubourg Saint-Antoine 75012 Paris."}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=16277"}],"version-history":[{"count":1,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16277\/revisions"}],"predecessor-version":[{"id":18223,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16277\/revisions\/18223"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=16277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=16277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=16277"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=16277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}